Teva Pharmaceuticals slammed with €462.6m fine for blocking Copaxone competitors

Pallavi Madhiraju- November 2, 2024 0

Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European Commission for anti-competitive practices related to its ... Read More

Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio

Pallavi Madhiraju- July 12, 2024 0

In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA ... Read More

Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746

Pallavi Madhiraju- August 25, 2023 0

Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase 1 clinical trials for its groundbreaking SARM1 ... Read More

Glenmark Pharmaceuticals introduces Fingolimod Capsules in US

Pallavi Madhiraju- November 15, 2022 0

India-based Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Inc., USA has introduced its Fingolimod Capsules, 0.5 mg in the US market. The product is ... Read More

Digital medicine firm Akili Interactive to merge with Social Capital Suvretta

Pallavi Madhiraju- January 29, 2022 0

Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), ... Read More

Novartis bags Kesimpta FDA approval for relapsing forms of MS

pharmanewsdaily- August 21, 2020 0

Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) ... Read More

Mylan gets favorable court decision in Biogen’s Tecfidera patent case

pharmanewsdaily- June 19, 2020 0

Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen's Tecfidera patent U.S. Patent No. ... Read More

Janssen’s Ponesimod OPTIMUM trial in MS meets primary endpoint

pharmanewsdaily- July 29, 2019 0

Ponesimod OPTIMUM trial results :  Johnson & Johnson's Janssen Pharmaceutical said that the phase 3 OPTIMUM clinical trial evaluating ponesimod yielded positive results compared to ... Read More

Convelo, Genentech to collaborate on remyelination drugs for MS

pharmanewsdaily- July 17, 2019 1

US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs ... Read More

Multiple Sclerosis symptoms may worsen with consumption of Soda, Sugar sweetened beverages

pharmanewsdaily- March 8, 2019 0

If people with multiple sclerosis consume 290 calories of soda or sugar sweetened beverages a day, their symptoms may worsen as warned by the researchers. ... Read More